NOV 09, 2017 1:30 PM PST

Importance of Measuring the Inhibition of Platelet Thromboxanes by Aspirin in Cardiovascular Disease Management and Prevention

Speaker
  • Medical Director, Corgenix Inc.
    Biography
      Luis R. Lopez, M.D., is the founder of Corgenix, Inc. (Broomfield, Colorado, USA) and currently serves as the Company's Medical Director. He received his MD degree in Lima, Peru, with Internal Medicine residency and postgraduate training in Clinical Immunology and Rheumatology at the University of Colorado Health Sciences Center in Denver Colorado. Dr. Lopez has worked in the field of immunodiagnostic of systemic autoimmune diseases including autoimmune-mediated atherothrombotic syndromes such as systemic lupus erythematosus (SLE) and antiphospholipid syndrome (APS). Recent work and publications have included serologic biomarkers to assess the risk of atherosclerotic cardiovascular diseases (CVD) such as oxidized low-density lipoprotein, ß2-Glycoprotein I and CRP complexes as well as pro-thrombotic platelet (urinary thromboxanes, 11dhTxB2) and inflammatory-derived F2-Isoprostanes metabolites.

    Abstract

    Antiplatelet therapy with aspirin (ASA) is widely used in cardiovascular disease (CVD) prevention because it inhibits platelet cyclooxygenase-1 (COX-1) and thromboxane A2 (TXA2)-mediated platelet aggregation, but not everyone fully benefit from ASA due to incomplete TXA2 suppression. Among the mechanisms to explain ASA failure (poor ASA response or ASA resistance), oxidative stress and inflammation have emerged as relevant factors. The relationship of urinary 11-dehydro-thromboxane B2 (11dhTxB2), an inactive stable metabolite of TxA2, and oxidative stress (urinary 8-isoPGF2α) in a cohort of stable coronary artery disease (CAD) patients on ASA treatment with the risk of adverse outcomes (mortality) was investigated. In this session, the effect of aspirin on platelet cyclooxygenase COX-1 and thromboxane (TxA2) inhibition, and its use in cardiovascular disease prevention will be reviewed. This review will include current laboratory measurement of urinary 11dhTxB2, a stable inactive metabolite of TxA2, to assess ASA response as a risk factor of CVD including mortality. Study results confirmed that laboratory measurement of urinary 11dhTxB2 represents a strong independent risk factor for all-cause mortality among stable CAD patients on ASA therapy. These results also indicate that 8-isoPGF2α and COX-2 thromboxane production not affected by ASA may maintain platelet hyperactivity irrespective of COX-1 inhibition. Poor ASA inhibition of 11dhTxB2 (ASA resistance) may prompt additional anti-oxidative and/or anti-inflammatory therapy in these patients aimed at modifying 5-year mortality risk.


    Show Resources
    You May Also Like
    APR 07, 2020 8:00 AM PDT
    C.E. CREDITS
    APR 07, 2020 8:00 AM PDT
    DATE: April 7, 2020 TIME: 8:00am PT, 11:00am ET This webinar sets out to establish why quality control is key to robust, reliable, reproducible science. We will look at best practice criteri...
    AUG 25, 2020 8:00 AM PDT
    C.E. CREDITS
    AUG 25, 2020 8:00 AM PDT
    DATE: August 25, 2020 TIME: 8:00am PDT, 10:00am CDT, 11:00am EDT Recombinant lentivirus (LV) and adeno-associated virus (AAV) are critical components of cell and gene therapies, which show g...
    JUN 09, 2020 10:00 AM PDT
    C.E. CREDITS
    JUN 09, 2020 10:00 AM PDT
    DATE: June 9, 2020 TIME: 10:00am PT, 1:00pm ET The presentation will first discuss sepsis as a disease and then explain the importance of performing diagnostic tests in the clinical labora...
    MAY 08, 2020 10:00 AM PDT
    C.E. CREDITS
    MAY 08, 2020 10:00 AM PDT
    DATE: May 8, 2020 TIME: 10:00am PT, 11:00am MT, 1:00pm ET The application of next generation sequencing to interrogate immune repertoires and methods in which these highly complex dataset...
    AUG 18, 2020 10:00 AM PDT
    C.E. CREDITS
    AUG 18, 2020 10:00 AM PDT
    DATE: August 18, 2020 TIME: 10:00am PT Get deeper understanding of gene expression patterns by using assays that retain spatial organization at single cell resolution! Come learn about the n...
    JUN 23, 2020 10:00 AM PDT
    C.E. CREDITS
    JUN 23, 2020 10:00 AM PDT
    DATE: June 23, 2020 TIME: 10:00am PT Human mesenchymal stromal or stem cells (MSCs)-based immunomodulation treatment has been proposed as a suitable therapeutic approach for many diseases, s...
    Loading Comments...
    Show Resources